文献速递神经肿瘤

整合分子分析揭示HOX基因高甲基化与过表达是IDH突变胶质瘤的不良预后因素

Integrated molecular analysis reveals hypermethylation and overexpression of HOX genes to be poor prognosticators in isocitrate dehydrogenase mutant glioma.
PubMed 文献 · Neuro Oncol · 2023-01-01

该研究对729例IDH突变胶质瘤样本进行整合分子分析,包括99例UHN测试集及DKFZ和TCGA两个验证队列。Cox回归识别出可强烈预测生存的CpG甲基化特征,并在验证队列中证实(所有P值<.0001)。HOX基因平行过表达与同时高甲基化与突变负荷增加、高非整倍体及更差生存显著相关,据此开发的7-HOX基因特征在1p/19q共缺失和非共缺失IDH突变胶质瘤中均显示显著生存差异。

要点

  • 基于UHN队列的CpG甲基化特征将IDH突变胶质瘤分为两个预后组,TCGA和DKFZ验证均P<.0001。
  • HOX基因过表达伴高甲基化与突变负荷增加、高非整倍体及更差生存相关(P<.0001)。
  • 7-HOX基因特征在1p/19q共缺失和非共缺失IDH突变胶质瘤中均显示显著生存差异。

核心结论

  • HOX基因甲基化和表达为IDH突变胶质瘤提供当前分子诊断未捕获的重要预后信息。
  • 7-HOX基因预后特征在1p/19q共缺失和非共缺失IDH突变胶质瘤中均显示显著生存差异。

研究设计与样本

  • 整合分子分析(甲基化、mRNA、拷贝数变异和突变数据)共分析729例IDH突变样本。
  • 测试集为University Health Network(UHN)的99例样本。
  • 验证队列包括德国癌症研究中心(DKFZ)和癌症基因组图谱(TCGA)两个独立队列。

主要发现

  • 对UHN队列甲基化数据的Cox回归分析识别出CpG特征,将胶质瘤队列分为2个强烈预测生存的预后组,并在TCGA和DKFZ两个独立队列中验证(所有P值<.0001)。
  • 预测不良结局的甲基化特征表现出高CNV不稳定性及HOX基因探针高甲基化。
  • 使用mRNA和甲基化的整合多平台分析(iRM)显示,HOX基因平行过表达与同时高甲基化显著关联于突变负荷增加、高非整倍体和更差生存(P值<.0001)。
  • 基于与患者结局最显著相关的HOX基因,开发了7-HOX基因特征,并在1p/19q共缺失和非共缺失IDH突变胶质瘤中验证。

关键数值与推荐

  • CpG甲基化特征将UHN队列分为2个预后组,TCGA和DKFZ验证均P<.0001。
  • HOX基因过表达伴高甲基化与更差生存相关,P值<.0001。
  • 7-HOX基因特征在1p/19q共缺失和非共缺失IDH突变胶质瘤中均显示显著生存差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diffuse gliomas represent over 80% of malignant brain tumors ranging from low-grade to aggressive high-grade lesions. Within isocitrate dehydrogenase (IDH)-mutant gliomas, there is a high variability in survival and a need to more accurately predict outcome. METHODS: To identify and characterize a predictive signature of outcome in gliomas, we utilized an integrative molecular analysis (using methylation, mRNA, copy number variation (CNV), and mutation data), analyzing a total of 729 IDH-mutant samples including a test set of 99 from University Health Network (UHN) and 2 validation cohorts including the German Cancer Research Center (DKFZ) and The Cancer Genome Atlas (TCGA). RESULTS: Cox regression analysis of methylation data from the UHN cohort identified CpG-based signatures that split the glioma cohort into 2 prognostic groups strongly predicting survival that were validated using 2 independent cohorts from TCGA and DKFZ (all P-values < .0001). The methylation signatures that predicted poor outcomes also exhibited high CNV instability and hypermethylation of HOX gene probes. Integrated multi-platform analyses using mRNA and methylation (iRM) showed that parallel HOX gene overexpression and simultaneous hypermethylation were significantly associated with increased mutational load, high aneuploidy, and worse survival (P-value < .0001). A 7-HOX gene signature was developed and validated using the most significantly associated HOX genes with patient outcome in both 1p/19q codeleted and non-codeleted IDHmut gliomas. CONCLUSIONS: HOX gene methylation and expression provide important prognostic information in IDH-mutant gliomas that are not captured by current molecular diagnostics. A 7-HOX gene signature of outcome shows significant survival differences in both 1p/19q codeleted and non-codeleted IDH-mutant gliomas.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Mamatjan Y, Voisin MR, Nassiri F, et al. Integrated molecular analysis reveals hypermethylation and overexpression of HOX genes to be poor prognosticators in isocitrate dehydrogenase mutant glioma. Neuro Oncol. 2023. PMID: 37474126. doi:10.1093/neuonc/noad126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。